Fig. 1

CD8⁺ T cells specific for HLA-A*0201/EBV-BMLF1-GLC peptide by pentamer are present in the peripheral blood of haplo-HSCT recipients. (a): PBMCs from an HLA*A0201(+) patient at + 60 days after haplo-HSCT. The four flow graphs show the flow gating and target cell sorting. Forward and side scatters were used to gate viable populations of the cells, and CD3⁺CD19⁻ cells were then gained to delete B lymphocytes. Subsequently, CD3⁺CD19⁻CD8⁺ cells were gained as CD8⁺ lymphocytes, and finally, HLA-A*0201-pentamer stained CD3⁺CD8⁺CD19⁻ cells were gained as the target cells for FACS analysis. (b): PBMCs from HLA*A0201- and HLA*A1101-negative controls were stained with anti-CD3-preCP monoclonal antibodies, anti-CD19-APC monoclonal antibodies, anti-CD8-FITC monoclonal antibodies, and HLA-A*0201/EBV-BMLF1-GLC pentamer-PE, and the cells were analyzed as described in (a)